Cargando…
RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade
BACKGROUND: Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches. METH...
Autores principales: | Heidegger, Simon, Kreppel, Diana, Bscheider, Michael, Stritzke, Florian, Nedelko, Tatiana, Wintges, Alexander, Bek, Sarah, Fischer, Julius C., Graalmann, Theresa, Kalinke, Ulrich, Bassermann, Florian, Haas, Tobias, Poeck, Hendrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444128/ https://www.ncbi.nlm.nih.gov/pubmed/30852164 http://dx.doi.org/10.1016/j.ebiom.2019.02.056 |
Ejemplares similares
-
Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines
por: Bek, Sarah, et al.
Publicado: (2019) -
P57. Activation of RIG-I induces immunogenic cell death
por: Bek, S, et al.
Publicado: (2014) -
Card9 controls Dectin‐1‐induced T‐cell cytotoxicity and tumor growth in mice
por: Haas, Tobias, et al.
Publicado: (2017) -
Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells
por: Fischer, Julius C., et al.
Publicado: (2019) -
Targeting RIG-I or STING promotes epithelial regeneration
por: Fischer, Julius C., et al.
Publicado: (2017)